About Pharma Industry

BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.

Novartis Ups Rhetoric v. "Terrorist" Animal Rights Activists; "Police Not Taking It Seriously"

By Jim Edwards | Aug 11, 2009

Novartis CEO Daniel Vasella and his company spokespersons have hit back at animal rights activists who burned his Austrian vacation home and stole his mother’s ashes from a grave: “How far do things have to go before you can speak of terrorism?” Vasella told a Swiss newspaper.

The attack seems to have gotten the attention of Novartis management, and caused a change of strategy, from quietly dealing with threats to publicly criticizing them. On the other side, arsonists seem to be enjoying the attention.

The arsonists are part of the campaign against Huntingdon Life Sciences, which does animal testing for drug companies. SwissInfo:

Vasella said Novartis has had no relationship whatsoever with the laboratory for some time now and that police have not taken the threats seriously enough.

Vasella called the grave desecration “unacceptable” and described it as an “unforgivable disrespect.”

Separately, a Novartis representative hinted that the situation with animal rights activists is getting worse:

‘The situation with SHAC has completely degenerated,’ he said, adding: ‘We take the security of our officials very seriously.’

What’s going on here? Vasella is clearly rattled and the company has decided that this is a “teachable moment” for the public. It is hard for ordinary people to sympathize with a millionaire CEO who flies to his hunting lodge via helicopter, but when the activists desecrated the Vasella family grave they crossed a line — and Novartis will use that as ammo against them.

Similarly, there seems to be a total contradiction — working in Novartis’ favor, at this point — between Novartis’ assertion that it has not done business with HLS for some time and SHAC’s position that Novartis is one of HLS’s top customers.

Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years, and is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. Follow him on Twitter or send him an email.

BNET User Analysis

Web Buzz:
  • What New Bristol-Myers CEO Can Expect: More Management Churn and Animal Rights Protests

    BNET Pharma - 11 days 2 hours 49 minutes ago

    The ascent of Lamberto Andreotti to CEO of Bristol-Myers Squibb (BMY) sets the stage for two events: Potential continued churn in BMS leadership and a renewed series of attacks from animal rights activists, for whom Andreotti is already a target. Andreotti (pictured below left) will be the third CEO at BMS in four years. Peter Dolan stepped...

  • Novartis To Give Vasella Too Much Of A Bonus

    Pharmalot - 39 days 5 hours 43 minutes ago

    Former Novartis ceo Dan Vasella’s 2009 bonus will be close to three times the amount he would be due based on relative earnings growth among large cap peers, according to a report compiled by UK proxy voting agency Manifest and Swiss consultancy Obermatt, Reuters writes. The estimated payout will total about $5.96 million. And that would be...

  • The New Man at Novartis

    BusinessWeek - 34 days 21 hours 3 minutes ago

    By Dermot Doherty Browse the BusinessWeek Archive Joe Jimenez says that more than 20 years selling Clorox (CLX) bleach and Heinz ketchup taught him to make decisions quickly. Now, as CEO of Novartis (NVS), Europe's second-largest drugmaker, he'll try to prove that speed can also make a difference in the pharmaceutical business. Jimenez, 50, is...

  • New Novartis chief scouting for 'bolt-on' buyouts

    FierceBiotech - 16 days 8 hours 38 minutes ago

    Newly-appointed Novartis CEO Joe Jimenez got his first chance to take the lead role at the annual shareholders' meeting today, and started to give the industry a better feel for just the kind of new acquisitions that will mark his tenure at the helm of the pharma giant. First, he told shareholders, don't look for any more big acquisitions...

  • Novartis Eyes Smaller-Than-Alcon Deals; Holders Okay ‘Say on Pay’

    WSJ Health Blog - 16 days 5 hours 42 minutes ago

    New Novartis chief Joe Jimenez (right) is looking at beefing up some business segments with acquisitions, but has nothing in mind as big as its $39.3 billion plan to buy the rest of eye-care company Alcon. ?We may go for smaller, bolt-on acquisitions to help build scale in vaccines, generics and consumer health, but we will not go for one of...

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a>)

advertisement
advertisement
advertisement